Dr. Peter Attia has declared war on what he calls the marginal decade, the final years of life that are often plagued by ...

But a new generation of noninvasive tests are emerging that could help accelerate diagnosis and improve management of this ...

Scientists are learning more about this leading complication of childbirth. Treatments are improving and doctors can test for ...

The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to help rule out Alzheimer’s disease in ...

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

Data at ESMO 2025 bolstered the case that blood tests could help doctors sort which patients need additional therapy, and who ...

The FDA has cleared the Elecsys pTau181 test as an aid in early detection of amyloid pathology in the primary care setting for adults aged 55 years and older presenting with signs, symptoms or ...

A new testing algorithm that integrates serum AAT levels, genotyping, and functional activity could significantly enhance the ...

In education, test scores often dominate the conversation — scrutinized by policymakers and used to compare and rank schools. However, for school leaders committed to personalized learning, a critical ...

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed ...

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.

The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...